Testing two chemo regimens for ovarian germ cell tumors
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This Phase 3 trial compares two different chemotherapy approaches for women with ovarian sex cord–stromal germ cell tumors. It aims to see which treatment works better and is safer for newly diagnosed stage IIA to IVB disease after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female, age 65 or younger, and Chinese
- Your diagnosis is confirmed as a specific type of ovarian sex cord–stromal tumor (for example granulosa, Sertoli-Leydig, or steroid cell tumor)
- You were newly diagnosed with stage IIA through IVB disease
- You had initial surgery (to diagnose, stage, or remove tumor) within the last 8 weeks
- Your blood tests and organ labs meet limits (white blood cells, neutrophils, platelets, liver and kidney function)
- You can have chemotherapy based on your overall health (Karnofsky score 60 or higher) and you agree to informed consent
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial tests two chemotherapy regimens (TC vs BEP) for women with malignant sex cord-stromal tumors of the ovary. It aims to see which treatment works better after you’ve had initial surgery to diagnose and/or remove tumor.
This trial tests a different way of giving chemotherapy to people with advanced ovarian cancer that didn't respond well to initial treatment. The goal is to see if changing the dose and schedule can improve outcomes.
This Phase 3 trial studies a three-step “extra” chemotherapy plan after surgery for people with certain advanced ovarian, fallopian-tube, or primary peritoneal cancers. The goal is to improve outcomes by lowering the chance the cancer comes back.
This trial compares two chemotherapy drugs (paclitaxel alone vs. paclitaxel plus carboplatin) given before surgery for advanced ovarian cancer. It is specifically for people whose tumors have a high level of the PARK2 gene, which may make them respond better to one of the treatments.
This trial tests an immune-based treatment (IMNN-001/GEN-1) combined with standard chemotherapy given before and during surgery. It’s for people with newly diagnosed advanced high-grade serous ovarian, fallopian tube, or primary peritoneal cancer to see if it can improve outcomes.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
Hear when a new Ovarian Neoplasms trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.